澳门js全球唯一官方网站|Macau·VIP主页

Synlogic announces initiation of Synpheny-3 global, pivotal phase 3 study evaluating SYNB1934 for PKU

Jun 5, 2023 — Registrational study designed to support BLA submission of first-in-class biotherapeutic.

FDA approves Seres’ microbiota drug for recurrent gut infection

Apr 26, 2023 — The drug is the first microbiota-based pill to win U.S. approval. Like a rival therapy approved in December, it’s for difficult-to-treat C. diff infections.

Synlogic announces positive top-line phase 2 data for phenylketonuria (PKU); SYNB1934 advances to phase 3

Oct 18, 2022 — Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population

Novome and Genentech enter into a strategic collaboration to develop targets against IBD

Nov 10, 2021 — Collaboration will leverage Novome’s GEMMs platform for colonizing the human gut with therapeutically engineered bacteria